BARCELONA, Spain—(UPDATED) Aspirin has long been the antiplatelet of choice for long-term secondary prevention in patients with coronary disease, but a meta-analysis of several trials suggests P2Y12 ...

Across the world, many patients with CVD still aren’t on the recommended medications for secondary prevention, according to more than a decade’s worth of data from the 17-country Prospective Urban ...

Objective: To apply the UK Medical Research Council (MRC) framework for development and evaluation of trials of complex interventions to a primary healthcare intervention to promote secondary ...

Please provide your email address to receive an email when new articles are posted on . The combination of icosapent ethyl, ezetimibe and rivaroxaban may lower risk for CV death, MI and stroke well ...

A polypill that includes key medications associated with improved outcomes (aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as a simple approach to the secondary ...

Please provide your email address to receive an email when new articles are posted on . Many people requiring secondary prevention drugs for CVD do not receive them. This trend persisted even in ...

Departments of Obstetrics and Gynecology and Medicine, MedStar Georgetown University Hospital and Georgetown University Medical Center, Washington, DC, USA Increased age- and sex-adjusted US fracture ...

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management ...

For many patients with venous thromboembolism, secondary prevention with vitamin K antagonists is not extended beyond six months, since the risk of recurrence may be outweighed by the risk of major ...